Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study

Acromegaly: An Endocrine Society Clinical Practice Guideline

Laurence Katznelson, Edward R. Laws, Mark E. Molitch et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 1.8K citations · Full text

Medicine, Endocrinology, Pharmacotherapy +15

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

Christian Bruns, Ian Lewis, U. Briner et al. · European Journal of Endocrinology · 2002 · 687 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

Mônica R. Gadelha, Marcello D. Bronstein, Thierry Brue et al. · The Lancet Diabetes & Endocrinology · 2014 · 402 citations

Medicine, Endocrinology, Pharmacotherapy +4

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Annamaria Colao, Marcello D. Bronstein, Pamela U. Freda et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 394 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

A. J. van der Lely, Beverly M. K. Biller, Thierry Brue et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 251 citations · Full text

Pharmacy, Endocrinology, Internal Medicine +17